Literature DB >> 27044597

Treatment of Osteochondritis Dissecans of the Talus in Skeletally Immature Population: A Critical Analysis of the Available Evidence.

Roberto Buda1, Gherardo Pagliazzi1, Francesco Castagnini2, Marco Cavallo1, Sandro Giannini1.   

Abstract

UNLABELLED: Juvenile osteochondritis dissecans of the talus (JOCDT) is a subchondral bone alteration and a partially or completely detached osteochondral fragment, affecting skeletally immature patients. A review of the English literature on PubMed was conducted. Conservative treatment was applied in patients up to Berndt-Harty stage III. Surgical indications were conservative management failure and loose bodies. The most performed procedures were drilling, subchondral bone grafting, fragment fixation, or excision. High rate of clinical success were achieved, whereas radiographic results were much lower. None of the surgical options demonstrated to be superior. Future long-term qualitative studies focusing on chondral tissue restoration are needed. LEVELS OF EVIDENCE: Therapeutic, Level IV.
© 2016 The Author(s).

Entities:  

Keywords:  conservative management; osteochondritis dissecans; pediatric population; skeletally immature population; treatment guidelines

Mesh:

Year:  2016        PMID: 27044597     DOI: 10.1177/1938640016640889

Source DB:  PubMed          Journal:  Foot Ankle Spec        ISSN: 1938-6400


  2 in total

1.  Re-operation rate after surgical treatment of osteochondral lesions of the talus in paediatric and adolescent patients.

Authors:  Daniel Körner; Christoph E Gonser; Stefan Döbele; Christian Konrads; Fabian Springer; Gabriel Keller
Journal:  J Orthop Surg Res       Date:  2021-03-15       Impact factor: 2.359

2.  Matrix-associated autologous chondrocyte implantation with autologous bone grafting of osteochondral lesions of the talus in adolescents: patient-reported outcomes with a median follow-up of 6 years.

Authors:  Daniel Körner; Christoph E Gonser; Stefan Döbele; Christian Konrads; Fabian Springer; Gabriel Keller
Journal:  J Orthop Surg Res       Date:  2021-04-08       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.